Physician profile
Daniel E Ling
NPI 1285964577
$1,423.80
in general payments reported to CMS, 2019-2025
14 companies · $27.79 in 2025
The $27.79 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $901 · 2020: $255 · 2021: $102 · 2022: $80.21 · 2023: $41.90 · 2024: $16.29 · 2025: $27.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $85.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $85.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $400.48 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $307.40 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $234.54 | 2019-2024 | Xarelto |
| Pfizer INC. | $163.71 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $54.14 | 2019-2022 | |
| Abbvie INC. | $49.56 | 2021 | |
| Novo Nordisk INC | $47.52 | 2023-2025 | Wegovy, Ozempic |
| Takeda Pharmaceuticals U.S.A., INC. | $46.65 | 2019 | |
| Neurocrine Biosciences, INC. | $29.59 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $24.46 | 2019 | |
| Cathworks, INC. | $22.17 | 2023 | Ffrangio |
| Amgen INC. | $19.56 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.63 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Ling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.